降脂药物研究进展

磊 石(内蒙古医科大学，中国;内蒙古自治区人民医院，中国;)
润秀 朱(内蒙古自治区人民医院，中国;)

摘要

动脉粥样硬化性心血管疾病（ASCVD）是全世界范围内危害最高的疾病之一，低密度脂蛋白胆固醇（LDL-C）升高是ASCVD最重要的危险因素之一，也是《中国血脂管理指南》建议的首要降脂干预靶点。他汀类药物是降低LDL-C的首选药物，但他汀类药的降脂作用并不能完全令人满意，并可能出现肌痛等不良反应，为更快更安全地达到LDL-C目标，研究人员发出多种针对不同作用靶点的降脂药物。论文综述了部分非他汀类药物降低LDL-C的药物的有效性及安全性。

关键词

动脉粥样硬化性心血管疾病（ASCVD）；低密度脂蛋白胆固醇（LDL-C）；降脂药物

参考

Kasichayanula, Sreeneeranj, Grover, et al. Clinical Pharmacokinetics and Pharmacodynamics of Evolocumab, a PCSK9 Inhibitor[J]. Clinical Pharmacokinetics, 2018.

Sabatine, Marc S, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease[J]. The New England journal of medicine, 2017,376(18): 1713-1722.

A M J K, B M S S, B R P G S, et al. Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia[J]. Journal of the American College of Cardiology, 2019, 74(17):2132-2146.

A B G, B F M, A J G M, et al. Cognition After Lowering LDL-Cholesterol With Evolocumab - ScienceDirect[J]. Journal of the American College of Cardiology, 2020, 75(18):2283-2293.

Schwartz, Gregory G, et al. Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial[J]. European heart journal, vol. 44,16 1408-1417. 5 Mar. 2023.

Goodman, Shaun G et al. Long-Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo-Controlled Observation in the ODYSSEY OUTCOMES Trial[J]. Journal of the American Heart Association, vol. 12,18 (2023): e029216.

D’Erasmo, Laura et al. Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey[J]. Orphanet journal of rare diseases,vol. 16,1 381. 8 Sep. 2021.

Reeskamp LF, Millar JS, et al. ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report[J]. Arterioscler Thromb Vasc Biol, 2021 May 5;41(5):1753-1759.

Zhang, Jing et al. A Randomized, Parallel, Open-Label, Single-Dose and Multiple-Dose Clinical Trial to Investigate the Pharmacokinetic, Pharmacodynamic, and Safety Profiles of Obicetrapib in Healthy Participants in China[J]. Journal of clinical pharmacology, 10.1002/jcph.

Nicholls, Stephen J et al. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial[J]. JAMA cardiology vol.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i11.22422